Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Liam G Heaney; Ratko Djukanovic; Ashley Woodcock; Samantha Walker; John G Matthews; Ian D Pavord; Peter Bradding; Robert Niven; Chris E Brightling; Rekha Chaudhuri; Joseph R Arron; David F Choy; Douglas Cowan; Adel Mansur; Andrew Menzies-Gow; Ian Adcock; Kian F Chung; Chris Corrigan; Peter Coyle; Timothy Harrison; Sebastian Johnston; Peter Howarth; James Lordan; Ian Sabroe; Jeannette Bigler; Dirk Smith; Matthew Catley; Richard May; Lisa Pierre; Chris Stevenson; Glenn Crater; Frank Keane; Richard W Costello; Val Hudson; David Supple; Tim Hardman; Matthew Cattley

doi:10.1136/thoraxjnl-2015-207326

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, Samantha Walker, John G Matthews, Ian D Pavord, Peter Bradding, Robert Niven, Chris E Brightling, Rekha Chaudhuri, Joseph R Arron, David F Choy, Douglas Cowan, Adel Mansur, Andrew Menzies-Gow, Ian Adcock, Kian F Chung, Chris Corrigan, Peter Coyle, Timothy HarrisonSebastian Johnston, Peter Howarth, James Lordan, Ian Sabroe, Jeannette Bigler, Dirk Smith, Matthew Catley, Richard May, Lisa Pierre, Chris Stevenson, Glenn Crater, Frank Keane, Richard W Costello, Val Hudson, David Supple, Tim Hardman, Matthew Cattley

Research output: Contribution to journal › Article › peer-review

Abstract

The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

Original language	English
Journal	Thorax
DOIs	https://doi.org/10.1136/thoraxjnl-2015-207326
Publication status	Published - 23 Jul 2015

Keywords

Asthma Mechanisms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/thoraxjnl-2015-207326

Cite this

Heaney, L. G., Djukanovic, R., Woodcock, A., Walker, S., Matthews, J. G., Pavord, I. D., Bradding, P., Niven, R., Brightling, C. E., Chaudhuri, R., Arron, J. R., Choy, D. F., Cowan, D., Mansur, A., Menzies-Gow, A., Adcock, I., Chung, K. F., Corrigan, C., Coyle, P., ... Cattley, M. (2015). Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax. https://doi.org/10.1136/thoraxjnl-2015-207326

@article{65a4498228a74aa3a4f293450bebb981,

title = "Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).",

abstract = "The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.",

keywords = "Asthma Mechanisms",

author = "Heaney, {Liam G} and Ratko Djukanovic and Ashley Woodcock and Samantha Walker and Matthews, {John G} and Pavord, {Ian D} and Peter Bradding and Robert Niven and Brightling, {Chris E} and Rekha Chaudhuri and Arron, {Joseph R} and Choy, {David F} and Douglas Cowan and Adel Mansur and Andrew Menzies-Gow and Ian Adcock and Chung, {Kian F} and Chris Corrigan and Peter Coyle and Timothy Harrison and Sebastian Johnston and Peter Howarth and James Lordan and Ian Sabroe and Jeannette Bigler and Dirk Smith and Matthew Catley and Richard May and Lisa Pierre and Chris Stevenson and Glenn Crater and Frank Keane and Costello, {Richard W} and Val Hudson and David Supple and Tim Hardman and Matthew Cattley",

year = "2015",

month = jul,

day = "23",

doi = "10.1136/thoraxjnl-2015-207326",

language = "English",

journal = "Thorax",

issn = "1468-3296",

publisher = "BMJ ",

}

Heaney, LG, Djukanovic, R, Woodcock, A, Walker, S, Matthews, JG, Pavord, ID, Bradding, P, Niven, R, Brightling, CE, Chaudhuri, R, Arron, JR, Choy, DF, Cowan, D, Mansur, A, Menzies-Gow, A, Adcock, I, Chung, KF, Corrigan, C, Coyle, P, Harrison, T, Johnston, S, Howarth, P, Lordan, J, Sabroe, I, Bigler, J, Smith, D, Catley, M, May, R, Pierre, L, Stevenson, C, Crater, G, Keane, F, Costello, RW, Hudson, V, Supple, D, Hardman, T & Cattley, M 2015, 'Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).', Thorax. https://doi.org/10.1136/thoraxjnl-2015-207326

TY - JOUR

T1 - Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

AU - Heaney, Liam G

AU - Djukanovic, Ratko

AU - Woodcock, Ashley

AU - Walker, Samantha

AU - Matthews, John G

AU - Pavord, Ian D

AU - Bradding, Peter

AU - Niven, Robert

AU - Brightling, Chris E

AU - Chaudhuri, Rekha

AU - Arron, Joseph R

AU - Choy, David F

AU - Cowan, Douglas

AU - Mansur, Adel

AU - Menzies-Gow, Andrew

AU - Adcock, Ian

AU - Chung, Kian F

AU - Corrigan, Chris

AU - Coyle, Peter

AU - Harrison, Timothy

AU - Johnston, Sebastian

AU - Howarth, Peter

AU - Lordan, James

AU - Sabroe, Ian

AU - Bigler, Jeannette

AU - Smith, Dirk

AU - Catley, Matthew

AU - May, Richard

AU - Pierre, Lisa

AU - Stevenson, Chris

AU - Crater, Glenn

AU - Keane, Frank

AU - Costello, Richard W

AU - Hudson, Val

AU - Supple, David

AU - Hardman, Tim

AU - Cattley, Matthew

PY - 2015/7/23

Y1 - 2015/7/23

N2 - The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

AB - The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

KW - Asthma Mechanisms

U2 - 10.1136/thoraxjnl-2015-207326

DO - 10.1136/thoraxjnl-2015-207326

M3 - Article

C2 - 26205878

SN - 1468-3296

JO - Thorax

JF - Thorax

ER -

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this